WO2009105507A3 - Beloxepin, its enantiomers, and analogs thereof for the treatment of pain - Google Patents

Beloxepin, its enantiomers, and analogs thereof for the treatment of pain Download PDF

Info

Publication number
WO2009105507A3
WO2009105507A3 PCT/US2009/034461 US2009034461W WO2009105507A3 WO 2009105507 A3 WO2009105507 A3 WO 2009105507A3 US 2009034461 W US2009034461 W US 2009034461W WO 2009105507 A3 WO2009105507 A3 WO 2009105507A3
Authority
WO
WIPO (PCT)
Prior art keywords
beloxepin
enantiomers
analogs
pain
treatment
Prior art date
Application number
PCT/US2009/034461
Other languages
French (fr)
Other versions
WO2009105507A2 (en
Inventor
Bertrand Le Bourdonnec
Roland Dolle
Original Assignee
Adolor Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to CA2715192A priority Critical patent/CA2715192A1/en
Priority to CN2009801138213A priority patent/CN102007139A/en
Priority to NZ587896A priority patent/NZ587896A/en
Priority to JP2010547737A priority patent/JP2011512414A/en
Priority to NZ594937A priority patent/NZ594937A/en
Priority to MX2010009110A priority patent/MX2010009110A/en
Application filed by Adolor Corporation filed Critical Adolor Corporation
Priority to AU2009215541A priority patent/AU2009215541A1/en
Priority to EP09712730A priority patent/EP2285818A4/en
Priority to BRPI0908098-8A priority patent/BRPI0908098A2/en
Publication of WO2009105507A2 publication Critical patent/WO2009105507A2/en
Publication of WO2009105507A3 publication Critical patent/WO2009105507A3/en
Priority to IL207668A priority patent/IL207668A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Reproductive Health (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Psychology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

This present disclosure provides methods of treating pain with beloxepin, beloxepin enantiomers, and analogs thereof.
PCT/US2009/034461 2008-02-19 2009-02-19 Beloxepin, its enantiomers, and analogs thereof for the treatment of pain WO2009105507A2 (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
CN2009801138213A CN102007139A (en) 2008-02-19 2009-02-19 Beloxepin, its enantiomers, and analogs thereof for the treatment of pain
NZ587896A NZ587896A (en) 2008-02-19 2009-02-19 Enantiomers of beloxepin, and the use of beloxepin and its enantiomers to treat pain and other disorders
JP2010547737A JP2011512414A (en) 2008-02-19 2009-02-19 Beroxepin, its enantiomers and analogs for treating pain
NZ594937A NZ594937A (en) 2008-02-19 2009-02-19 Beloxepin, its enantiomers, and analogs thereof for the treatment of pain
MX2010009110A MX2010009110A (en) 2008-02-19 2009-02-19 Beloxepin, its enantiomers, and analogs thereof for the treatment of pain
CA2715192A CA2715192A1 (en) 2008-02-19 2009-02-19 Beloxepin, its enantiomers, and analogs thereof for the treatment of pain
AU2009215541A AU2009215541A1 (en) 2008-02-19 2009-02-19 Beloxepin, its enantiomers, and analogs thereof for the treatment of pain
EP09712730A EP2285818A4 (en) 2008-02-19 2009-02-19 Beloxepin, its enantiomers, and analogs thereof for the treatment of pain
BRPI0908098-8A BRPI0908098A2 (en) 2008-02-19 2009-02-19 Beloxepine, composition, methods for treating pain in a mammal, for inhibiting ne reuptake, for antagonizing a 5ht2 receptor, and for treating a disorder in a patient who is responsive to treatment with a nri compound and a 5ht2 antagonist compound
IL207668A IL207668A0 (en) 2008-02-19 2010-08-18 Beloxepin, its enantiomers, and analogs thereof for the treatment of pain

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US2991508P 2008-02-19 2008-02-19
US2991308P 2008-02-19 2008-02-19
US2991608P 2008-02-19 2008-02-19
US61/029,916 2008-02-19
US61/029,915 2008-02-19
US61/029,913 2008-02-19
US5092108P 2008-05-06 2008-05-06
US61/050,921 2008-05-06

Publications (2)

Publication Number Publication Date
WO2009105507A2 WO2009105507A2 (en) 2009-08-27
WO2009105507A3 true WO2009105507A3 (en) 2010-01-14

Family

ID=40986169

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/034461 WO2009105507A2 (en) 2008-02-19 2009-02-19 Beloxepin, its enantiomers, and analogs thereof for the treatment of pain

Country Status (11)

Country Link
EP (1) EP2285818A4 (en)
JP (1) JP2011512414A (en)
KR (1) KR20100137473A (en)
CN (1) CN102007139A (en)
AU (1) AU2009215541A1 (en)
BR (1) BRPI0908098A2 (en)
CA (1) CA2715192A1 (en)
IL (1) IL207668A0 (en)
MX (1) MX2010009110A (en)
NZ (2) NZ594937A (en)
WO (1) WO2009105507A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090233959A1 (en) 2008-02-19 2009-09-17 Adolor Corporation Beloxepin and analogs for the treatment of pain
BR112017018297B1 (en) 2015-02-25 2023-12-05 The Regents Of The University Of California USE OF A 5HT RECEPTOR AGONIST SELECTED FROM TRAZODONE AND LORCARSERINE, OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND USE OF A 5HT RECEPTOR AGONIST SELECTED FROM CLEMIZOLE, A CLEMIZOLE ANALOGUE, OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF
CN106243096B (en) * 2016-07-29 2019-11-29 上海璃道医药科技有限公司 The new application of tricyclic drugs
US10966938B2 (en) 2019-01-04 2021-04-06 Jonand4, Llc Composition and method for preventing or treating hangover symptoms

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997044326A1 (en) * 1996-05-23 1997-11-27 F. Hoffmann-La Roche Ag Aryl pyrimidine derivatives
WO2001062341A2 (en) * 2000-02-22 2001-08-30 Knoll Gmbh Combination product for the treatment of obesity
WO2004052461A1 (en) * 2002-12-11 2004-06-24 Pharmacia & Upjohn Company Llc Combination for the treatment of adhd
WO2005042501A1 (en) * 2003-11-03 2005-05-12 Warner-Lambert Company Llc Novel norepinephrine reuptake inhibitors for the treatment of central nervous system disorders
WO2006065600A2 (en) * 2004-12-13 2006-06-22 Arena Pharmaceuticals, Inc. N-biaryl and n-arylheteroaryl piperazine derivatives as modulators of the 5ht2c receptor useful for the treatment of disorders related thereto
WO2006079637A1 (en) * 2005-01-27 2006-08-03 Janssen Pharmaceutica N.V. Heterocyclic tetracyclic tetrahydrofuran derivatives as 5ht2 inhibitors in the treatment of cns disorders
US20060293309A1 (en) * 2005-03-28 2006-12-28 Dynogen Pharmaceuticals, Inc. Method of treating disorders and conditions using peripherally-restricted antagonists and inhibitors
WO2007041258A1 (en) * 2005-09-29 2007-04-12 Wyeth Benzothiadiazolyphenylalkylamine derivatives for use in the treatment of conditions ameliorated by monoamine reuptake
WO2007112453A2 (en) * 2006-03-28 2007-10-04 Neopro Labs, Llc Methods amd compositions for treating conditions
WO2007129111A1 (en) * 2006-05-03 2007-11-15 Merck Sharp & Dohme Limited Diazepine derivatives as 5-ht2a antagonists
WO2007142923A1 (en) * 2006-05-31 2007-12-13 Avigen, Inc. Mif inhibitors for treating neuropathic pain and associated syndromes

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE62754B1 (en) * 1988-08-26 1995-02-22 Akzo Nv Tetracyclic antidepressants
US5663178A (en) 1995-02-06 1997-09-02 Eli Lilly And Company Tetrahydro-beta carbolines
US5952331A (en) 1996-05-23 1999-09-14 Syntex (Usa) Inc. Aryl pyrimidine derivatives
GB0019950D0 (en) 2000-08-12 2000-09-27 Smithkline Beecham Plc Compounds

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997044326A1 (en) * 1996-05-23 1997-11-27 F. Hoffmann-La Roche Ag Aryl pyrimidine derivatives
WO2001062341A2 (en) * 2000-02-22 2001-08-30 Knoll Gmbh Combination product for the treatment of obesity
WO2004052461A1 (en) * 2002-12-11 2004-06-24 Pharmacia & Upjohn Company Llc Combination for the treatment of adhd
WO2005042501A1 (en) * 2003-11-03 2005-05-12 Warner-Lambert Company Llc Novel norepinephrine reuptake inhibitors for the treatment of central nervous system disorders
WO2006065600A2 (en) * 2004-12-13 2006-06-22 Arena Pharmaceuticals, Inc. N-biaryl and n-arylheteroaryl piperazine derivatives as modulators of the 5ht2c receptor useful for the treatment of disorders related thereto
WO2006079637A1 (en) * 2005-01-27 2006-08-03 Janssen Pharmaceutica N.V. Heterocyclic tetracyclic tetrahydrofuran derivatives as 5ht2 inhibitors in the treatment of cns disorders
US20060293309A1 (en) * 2005-03-28 2006-12-28 Dynogen Pharmaceuticals, Inc. Method of treating disorders and conditions using peripherally-restricted antagonists and inhibitors
WO2007041258A1 (en) * 2005-09-29 2007-04-12 Wyeth Benzothiadiazolyphenylalkylamine derivatives for use in the treatment of conditions ameliorated by monoamine reuptake
WO2007112453A2 (en) * 2006-03-28 2007-10-04 Neopro Labs, Llc Methods amd compositions for treating conditions
WO2007129111A1 (en) * 2006-05-03 2007-11-15 Merck Sharp & Dohme Limited Diazepine derivatives as 5-ht2a antagonists
WO2007142923A1 (en) * 2006-05-31 2007-12-13 Avigen, Inc. Mif inhibitors for treating neuropathic pain and associated syndromes

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PAANAKKER, J.E. ET AL.: "Validation of an LC-MS assay for the quantification of the enantiomers of Org 4428 in human plasma", JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS., vol. 16, 28 October 1998 (1998-10-28), pages 981 - 989 *

Also Published As

Publication number Publication date
CA2715192A1 (en) 2009-08-27
IL207668A0 (en) 2010-12-30
EP2285818A4 (en) 2011-08-17
CN102007139A (en) 2011-04-06
NZ587896A (en) 2011-09-30
WO2009105507A2 (en) 2009-08-27
JP2011512414A (en) 2011-04-21
EP2285818A2 (en) 2011-02-23
AU2009215541A1 (en) 2009-08-27
MX2010009110A (en) 2010-11-30
NZ594937A (en) 2013-03-28
KR20100137473A (en) 2010-12-30
BRPI0908098A2 (en) 2015-08-18

Similar Documents

Publication Publication Date Title
PH12017500930A1 (en) Hsp90 inhibitor combinations
MX2011007930A (en) Crystalline insulin-conjugates.
BRPI0814941A2 (en) COMPOSITION OF SEED TREATMENT, AND, SEED TREATMENT METHOD.
EP2260109A4 (en) Microrna-based methods and compositions for the diagnosis, pronosis and treatment of prostate related disorders
WO2009129246A3 (en) Compositions and methods for preparing and using same
MX2014011134A (en) Carbamate compounds and of making and using same.
MY173616A (en) Compositions and methods for lowering triglycerides
WO2008063842A3 (en) Methods of treating neuropathic pain with agonists of ppar-gamma
MX2010007490A (en) Preparation of sulfamide derivatives.
EP2337535A4 (en) Systems, devices and methods for the treatment of tinnitus
WO2011047091A9 (en) Methods for treating traumatic brain injury
IL211313A0 (en) Compounds, compositions and methods for the treatment of ??-amyloid diseases and synucleinopathies
WO2010088450A3 (en) Arylamide derivatives useful in the treatment of diseases associated with serca activity
WO2013120022A3 (en) Treatment of hypoglycemia
WO2012017321A3 (en) Treatment for dyslipidemia
GB2465814B (en) Method,composition and device for the treatment of enzymes and saccharides disorders
EP2207555A4 (en) Novel compounds for the treatment or alleviation of edema, and methods for their use
WO2009120368A3 (en) Treatment of brain damage using umbilical cord blood cells
WO2009102789A3 (en) Use of rxr agonists for the treatment of osteroarthritis
WO2009105507A3 (en) Beloxepin, its enantiomers, and analogs thereof for the treatment of pain
WO2012082942A3 (en) Neuropeptide analogs, compositions, and methods for treating pain
WO2008085927A3 (en) Methods, compositions, and kits for the treatment of pain
WO2011084523A3 (en) Ulk1 compositions, inhibitors, screening and methods of use
EP2246533A4 (en) Sliding member, and method for treating surface of the sliding member
GB0821501D0 (en) Method, composition, and device, for the treatment of enzymes and saccharides disorder

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200980113821.3

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09712730

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 207668

Country of ref document: IL

Ref document number: 2715192

Country of ref document: CA

Ref document number: 2010547737

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2009215541

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2009712730

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 587896

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 1952/MUMNP/2010

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 2009215541

Country of ref document: AU

Date of ref document: 20090219

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 20107021010

Country of ref document: KR

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: PI0908098

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20100819